The European Commission has granted conditional marketing authorization to Zemcelpro, developed by ExCellThera, the first cell therapy in Europe designed for blood cancer patients lacking matched donors. Utilizing cord blood expansion technology, Zemcelpro offers a novel treatment option, expanding access for patients with limited donor availability. This regulatory milestone marks a significant advancement in cell therapy accessibility and cancer treatment innovation within the European Union.